Scaltriti et al. showed that lapatinib enhanced the effects of trastuzumab by inducing HER-2 stabilization and accumulation at the cell surface of breast cancer cell lines [24], and Mimura et al. reported that lapatinib induced accumulation of HER-2 and EGFR on esophageal cancer cell lines evoking trastuzumab- and cetuximab- mediated ADCC [25]. This evidence concerns the gene ERBB2 and esophageal cancer.